Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sabestomig?

Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Non-Small Cell Lung Carcinoma.

Apr 17, 2024 - 00:00
Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Non-Small Cell Lung Carcinoma.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-...

Next Article

With its squishy synthetic platelets, the startup SelSym seeks to reduce risk fr...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BGB-26808 by BeiGene for Solid Tumor: Likelihood of App...

Oct 3, 2023

Opinion: PEPFAR has been a lifeline in Ukraine. Now it’s under threat

Opinion: PEPFAR has been a lifeline in Ukraine. Now it’...

Dec 1, 2023

Holoclara gains Series A financing for worm-derived therapies

Holoclara gains Series A financing for worm-derived the...

Jun 30, 2024